Adverum Biotechnologies (ADVM) News Today → Executive Order To Wipe Out Your Bank Accounts (From Oasis Gold) (Ad) Free ADVM Stock Alerts $7.35 -0.10 (-1.34%) (As of 06/7/2024 08:51 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 29, 2024 | marketbeat.comAdverum Biotechnologies, Inc. (NASDAQ:ADVM) Sees Significant Drop in Short InterestAdverum Biotechnologies, Inc. (NASDAQ:ADVM - Get Free Report) saw a large drop in short interest during the month of May. As of May 15th, there was short interest totalling 762,200 shares, a drop of 36.5% from the April 30th total of 1,200,000 shares. Based on an average daily trading volume, of 308,400 shares, the days-to-cover ratio is presently 2.5 days. Approximately 5.9% of the shares of the company are sold short.May 27, 2024 | marketbeat.comStockNews.com Upgrades Adverum Biotechnologies (NASDAQ:ADVM) to "Hold"StockNews.com raised shares of Adverum Biotechnologies from a "sell" rating to a "hold" rating in a report on Monday.May 25, 2024 | marketbeat.comAdverum Biotechnologies, Inc. (NASDAQ:ADVM) Receives Consensus Rating of "Buy" from AnalystsAdverum Biotechnologies, Inc. (NASDAQ:ADVM - Get Free Report) has earned an average rating of "Buy" from the four analysts that are currently covering the company, MarketBeat Ratings reports. Four analysts have rated the stock with a buy rating. The average twelve-month target price among brokersMay 15, 2024 | marketbeat.comAdverum Biotechnologies (NASDAQ:ADVM) Earns "Buy" Rating from Truist FinancialTruist Financial reaffirmed a "buy" rating and issued a $60.00 price objective on shares of Adverum Biotechnologies in a research report on Wednesday.May 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Adverum’s Gene Therapy on Promising Interim Phase 2 Results and Potential Standard of Care Shift in nAMD TreatmentMay 10, 2024 | finance.yahoo.comAdverum Biotechnologies Reports Q1 2024 Results: A Detailed Look at Financials and Pipeline ProgressMay 10, 2024 | marketbeat.comAdverum Biotechnologies' (ADVM) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright reiterated a "buy" rating and set a $30.00 price target on shares of Adverum Biotechnologies in a research report on Friday.May 10, 2024 | investorplace.comADVM Stock Earnings: Adverum Biotechnologies Misses EPS for Q1 2024May 9, 2024 | chron.comAdverum Biotechnologies: Q1 Earnings SnapshotMay 9, 2024 | globenewswire.comAdverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline HighlightsMay 9, 2024 | finance.yahoo.comAre Medical Stocks Lagging Ligand Pharmaceuticals (LGND) This Year?May 3, 2024 | globenewswire.comAdverum Biotechnologies to Participate in Upcoming May Investor ConferencesMay 2, 2024 | marketbeat.comHC Wainwright Weighs in on Adverum Biotechnologies, Inc.'s Q1 2024 Earnings (NASDAQ:ADVM)Adverum Biotechnologies, Inc. (NASDAQ:ADVM - Free Report) - Equities researchers at HC Wainwright issued their Q1 2024 earnings per share (EPS) estimates for Adverum Biotechnologies in a research report issued to clients and investors on Tuesday, April 30th. HC Wainwright analyst M. Caufield antiApril 30, 2024 | marketbeat.comAdverum Biotechnologies, Inc. (NASDAQ:ADVM) Given Consensus Rating of "Buy" by AnalystsShares of Adverum Biotechnologies, Inc. (NASDAQ:ADVM - Get Free Report) have been given a consensus rating of "Buy" by the four ratings firms that are covering the stock, MarketBeat Ratings reports. Four analysts have rated the stock with a buy rating. The average 1-year price target among brokeraApril 30, 2024 | marketbeat.comAdverum Biotechnologies (NASDAQ:ADVM) Research Coverage Started at HC WainwrightHC Wainwright assumed coverage on Adverum Biotechnologies in a report on Tuesday. They set a "buy" rating and a $30.00 target price on the stock.April 29, 2024 | marketbeat.comMizuho Cuts Adverum Biotechnologies (NASDAQ:ADVM) Price Target to $22.00Mizuho cut their target price on shares of Adverum Biotechnologies from $40.00 to $22.00 and set a "buy" rating for the company in a research report on Monday.April 25, 2024 | globenewswire.comAdverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific MeetingApril 18, 2024 | money.usnews.comAdverum Biotechnologies IncMarch 28, 2024 | markets.businessinsider.comAnalysts Are Neutral on These Healthcare Stocks: SAGE Therapeutics (SAGE), Adverum Biotechnologies (ADVM)March 27, 2024 | marketbeat.comAdverum Biotechnologies, Inc. (NASDAQ:ADVM) Sees Large Decline in Short InterestAdverum Biotechnologies, Inc. (NASDAQ:ADVM - Get Free Report) was the target of a significant decline in short interest in the month of March. As of March 15th, there was short interest totalling 648,500 shares, a decline of 88.1% from the February 29th total of 5,430,000 shares. Approximately 4.3% of the company's shares are short sold. Based on an average daily trading volume, of 231,700 shares, the short-interest ratio is presently 2.8 days.March 22, 2024 | marketbeat.comChardan Capital Comments on Adverum Biotechnologies, Inc.'s FY2024 Earnings (NASDAQ:ADVM)Adverum Biotechnologies, Inc. (NASDAQ:ADVM - Free Report) - Equities research analysts at Chardan Capital increased their FY2024 EPS estimates for Adverum Biotechnologies in a research report issued on Tuesday, March 19th. Chardan Capital analyst D. Gataulin now expects that the biotechnology comMarch 21, 2024 | markets.businessinsider.comPositive Outlook for Adverum Biotechnologies with Upcoming Ixo-vec Milestones and Strong Financial PositionMarch 21, 2024 | marketbeat.comTrading was temporarily halted for "ADVM" at 07:03 PM with a stated reason of "News pending."March 20, 2024 | finance.yahoo.comAdverum Biotechnologies Reports Encouraging Clinical Progress Amidst Financial AdjustmentsMarch 19, 2024 | finance.yahoo.comIs Adverum Biotechnologies (ADVM) Stock Outpacing Its Medical Peers This Year?March 19, 2024 | marketbeat.comChardan Capital Reiterates Buy Rating for Adverum Biotechnologies (NASDAQ:ADVM)Chardan Capital reaffirmed a "buy" rating and set a $4.00 price objective on shares of Adverum Biotechnologies in a report on Tuesday.March 19, 2024 | marketbeat.comAdverum Biotechnologies (NASDAQ:ADVM) PT Lowered to $2.00 at Royal Bank of CanadaRoyal Bank of Canada decreased their target price on shares of Adverum Biotechnologies from $3.00 to $2.00 and set a "sector perform" rating on the stock in a research note on Tuesday.March 19, 2024 | markets.businessinsider.comAdverum Biotechnologies (ADVM) Receives a Buy from TD CowenMarch 18, 2024 | investorplace.comADVM Stock Earnings: Adverum Biotechnologies Beats EPS for Q4 2023March 18, 2024 | globenewswire.comAdverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate UpdatesMarch 17, 2024 | seekingalpha.comADVM Adverum Biotechnologies, Inc.March 8, 2024 | marketbeat.comFmr LLC Sells 1,069,367 Shares of Adverum Biotechnologies, Inc. (NASDAQ:ADVM)Fmr LLC lowered its stake in Adverum Biotechnologies, Inc. (NASDAQ:ADVM - Free Report) by 13.8% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 6,691,925 shares of the biotechnology company's stock after selling 1,069,36March 6, 2024 | finance.yahoo.comADVM Apr 2024 5.000 callMarch 6, 2024 | investorplace.comTurn Pocket Change into Profit: 3 Penny Stocks Ready to PopFebruary 28, 2024 | globenewswire.comAdverum Biotechnologies to Participate in the TD Cowen 44th Annual Health Care ConferenceFebruary 27, 2024 | investorplace.comStocks on the Launchpad: The Next 3 Market SensationsFebruary 25, 2024 | msn.comAdverum Biotechnologies (ADVM) Price Target Increased by 10.53% to 4.28February 22, 2024 | benzinga.comAdverum Biotechnologies Stock (NASDAQ:ADVM), Short Interest ReportFebruary 22, 2024 | investorplace.comUnleash Massive Returns With These 3 Top Penny StocksFebruary 15, 2024 | finance.yahoo.comADVM Feb 2024 4.000 callFebruary 13, 2024 | finance.yahoo.comADVM Sep 2024 2.500 putFebruary 12, 2024 | finance.yahoo.comAdverum Biotechnologies to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceFebruary 9, 2024 | uk.investing.comAdverum Biotechnologies Inc (ADVM)February 9, 2024 | marketbeat.comJames Paul Scopa Buys 100,000 Shares of Adverum Biotechnologies, Inc. (NASDAQ:ADVM) StockAdverum Biotechnologies, Inc. (NASDAQ:ADVM - Get Free Report) Director James Paul Scopa bought 100,000 shares of the company's stock in a transaction dated Wednesday, February 7th. The shares were acquired at an average cost of $1.35 per share, with a total value of $135,000.00. Following the acquisition, the director now directly owns 100,000 shares of the company's stock, valued at $135,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.February 8, 2024 | msn.comWhy Is Blindness Focused-Adverum Biotechnologies Stock Trading Lower Today?February 8, 2024 | finance.yahoo.comAdverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMDFebruary 8, 2024 | marketbeat.comTrading was temporarily halted for "ADVM" at 09:02 AM with a stated reason of "LULD pause."February 7, 2024 | msn.comAdverum Biotechnologies Awaits Court Decision on SettlementFebruary 6, 2024 | marketbeat.comAdverum Biotechnologies (NASDAQ:ADVM) Given New $4.00 Price Target at MizuhoMizuho raised their price objective on Adverum Biotechnologies from $2.00 to $4.00 and gave the company a "buy" rating in a research note on Tuesday.February 6, 2024 | msn.comAdverum Biotechnologies Secures $127.8M in Private Placement Get Adverum Biotechnologies News Delivered to You Automatically Sign up to receive the latest news and ratings for ADVM and its competitors with MarketBeat's FREE daily newsletter. Email Address Executive Order To Wipe Out Your Bank Accounts (Ad)Don't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of opportunity to protect your interests is closing fast. Click Here To Get Your FREE Guide Now! ADVM Media Mentions By Week ADVM Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ADVM News Sentiment▼0.000.77▲Average Medical News Sentiment ADVM News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ADVM Articles This Week▼01▲ADVM Articles Average Week Get Adverum Biotechnologies News Delivered to You Automatically Sign up to receive the latest news and ratings for ADVM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: SGMO News HLVX News ITOS News TSHA News VALN News EXAI News KYTX News ADPT News CABA News ALEC News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ADVM) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredAlert: Your Bank is Dying – Act Now or Lose Everything!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put...Priority Gold | SponsoredIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...Smallcaps Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | Sponsored